As intensive treatment to lower levels of HbA1c characteristically results in an increased risk
of hypoglycaemia, patients with diabetes mellitus face a life-long optimization problem to …

The control of diabetes is an interdisciplinary endeavor, which includes a significant
biomedical engineering component, with traditions of success beginning in the early 1960s …

Background Tight control of blood glucose in type 1 diabetes delays onset of macrovascular
and microvascular diabetic complications; however, glucose levels need to be closely …

Point‐of‐care testing (POCT) of clinical biomarkers is critical to health monitoring and timely
treatment, yet biosensing assays capable of detecting biomarkers without the need for costly …

Underutilization of glucose data and lack of easy and standardized glucose data collection,
analysis, visualization, and guided clinical decision making are key contributors to poor …

Background Recent studies have shown that an artificial-pancreas system can improve
glucose control and reduce nocturnal hypoglycemia. However, it is not known whether such …

Background: Glycemic variability has been proposed as a contributing factor in the
development of diabetes complications. Multiple measures exist to calculate the magnitude …

We review clinical instances in which A1C should not be used and reflect on the use of other
glucose metrics that can be used, in substitution of or in combination with A1C and SMBG, to …

Problematic hypoglycemia, defined as two or more episodes per year of severe
hypoglycemia or as one episode associated with impaired awareness of hypoglycemia …

Glycated hemoglobin A 1c (A1C) levels have traditionally been the gold standard for
assessing glycemic control and treatment efficacy in patients with type 2 diabetes. However …